| Name | Title | Contact Details |
|---|
"At EMD Millipore, one of the top three investors in R&D in the Life Science Tools industry, we develop cutting-edge technologies and services for bioscience research and biopharmaceutical manufacturing. Innovation drives everything we do. And it’s reinforced by our collaborative culture, pioneering spirit and unwavering focus on the world’s most challenging human health issues. EMD Millipore, known outside North America as Merck Millipore, is part of the Merck Group, a global company with 40,000 employees in more than 60 countries. EMD Millipore is a division of Merck KGaA, Darmstadt, Germany."
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Wallace Pharma is a Decatur, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Georgia Atkison Snf is a El Monte, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cor is a powerful general wellness product that delivers personalized health insights from a single drop of blood. The Cor Reader uses patented vibrational spectroscopic technology to analyze a surface-level blood sample and report overall trends. The Cor App then delivers key insights and lifestyle improvement recommendations related to indicators such as cholesterol, fasting blood glucose, inflammation and triglycerides. Cor was founded in 2014 by Bob Messerschmidt and is backed by world-class medical advisors from Stanford, UCSF and Duke University.